U87 and U373 glioblastoma lines were originally acquired from the University of Uppsala (Uppsala, Sweden), and 293FT cells were acquired from ATCC (Manassas, VA, USA). All cell lines were cultured as previously described in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO₂ (33). All tetracycline inductions were accomplished at 2 µg/ml doxycycline in complete DMEM.

U87 cells were engineered to overexpress MARCKS or the MARCKS ED mutants in a tetracycline-dependent manner as previously described (25). Other ED mutants were similarly constructed. Concisely, the ViraPower HiPerform T-REx Gateway Expression System (cat. no. A11141) and the pENTR221 entry vector containing the wild-type (WT) sequence was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The pENTR221-MARCKS vector was cloned into the pLenti6.3/TO/V5-DEST destination vector. Mutant MARCKS ED constructs were synthesized by and cloned into the pUC57 vector by GenScript (Piscataway, NJ, USA). Fragments from these plasmids with the mutations were cloned into the pLenti6.3/TO/V5-MARCKS-WT using restriction sites and standard protocols to generate MARCKS mutant lentiviral plasmids containing blasticidin resistance and a V-5 epitope tag. An empty vector control plasmid (CTL) was also generated.

Lentiviral particles were produced as previously described (33). Concisely, lentivirus was generated by co-transfection of 293FT cells with an appropriate amount of MARCKS pLenti6.3/TO/V5 plasmid, pCMV-VSV-G envelope plasmid (Addgene plasmid 8454) and psPAX2 packaging plasmid (Addgene plasmid 12260) (both from Addgene, Watertown, MA, USA) with Lipofectamine 2000 (cat. no. 11668) in Opti-MEM (cat. no. 11058) (both from Thermo Fisher Scientific). The medium was changed the following morning, and enriched viral medium was collected 24 h later, filtered through a 0.45-µm filter, aliquoted and stored at -80°C. Lentivirus was quantified using QuickTiter p24 ELISA (Cell Biolabs, Inc., San Diego, CA, USA).

U87 cells were first transduced with p24 quantified tetracycline-repressor (Tet-R) packaged lentiviral particles along with 8 µg/ml polybrene as previously described (25). A total of 500 µg/ml Geneticin (G418; Life Technologies/Thermo Fisher Scientific) was used to select for Tet-R-positive cells. Tet-R-positive cells were subsequently transduced with similar amounts of p24 quantified CTL, WT+, NP, PP or ΔED lentiviral particles. Subsequently, 1 µg/ml blasticidin was used to select successfully transduced cells. Robust tetracycline-dependent MARCKS expression was validated by western blot analysis following a 72-h induction with 2 µg/ml of doxycycline (Life Technologies/Thermo Fisher Scientific) or the phosphate-buffered saline vehicle control. MARCKS mutations were additionally validated by PCR amplification using CMV forward primer (5′-CGCAAATGGGCGGTAGGCGTG-3′) and V5 reverse primer (5′-ACCGAGGAGAGGGTTAGGGAT-3′) coupled and sequenced using Sanger sequencing of an internal MARCKS forward primer (5′-GAACGGACAGGAGGATGG-3′) and V5 reverse primer (5′-ACCGAGGAGAGGGTTAGGGAT-3′).

Western blot analysis was performed as previously described (35). Briefly, chilled mammalian protein extraction reagent (MPER) lysis buffer (cat. no. 78501; Pierce/Thermo Fisher Scientific, Rockford, IL, USA) was supplemented with protease (#P8340) and phosphatase inhibitors (P0044 and P5726) (both from Sigma-Aldrich, St. Louis, MO, USA) before lysing the cells for 30 min on ice. The samples were subsequently centrifuged at 12,000 × g for 10 min at 4°C, and the supernatant was collected and quantified using the Pierce BCA protein assay kit. Samples were separated by electrophoresis through a 10% SDS-polyacrylamide gel (SDS-PAGE) and transferred onto a PVDF membrane (Immobilon, Emdmilipore, Burlington, MA, USA). The blots were blocked in 5% BSA for 1 h and probed with the following antibodies at 4°C overnight with gentle rocking using manufacturer recommended dilutions: V5-HRP (P/N 46-0708; Invitrogen/Thermo Fisher Scientific), MARCKS anti-rabbit (ab52616), MARCKS anti-mouse (ab55451) (both from Abcam, Cambridge, MA, USA), phosphorylated (p-)histone H2AX S139 (9718S), p-Akt (Ser473; D9E; #4060), p-Akt (Thr308; C31E5E; #2965), Akt (C67E7; #4691), PKCα (#2056) (all from Cell Signaling Technology, Danvers, MA, USA), rabbit IgG control (20304E; Imgenex/Novus Biologicals, Centennial, CO, USA) and Actin (sc-1616-R), lamin A/C (sc-7292), α-tubulin (sc-53646) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blots were treated with secondary HRP antibody at 1:5,000 for 1 h at room temperature with gentle rocking, and detected with enhanced chemiluminescence (ECL) using Western Lighting-Plus ECL substrate (PerkinElmer, Inc., Waltham, MA, USA) and blue X-ray film. Densitometry was performed using ImageJ software with 8-bit images and normalized to the loading control.

Plate and doxycycline induce for 72 h a sufficient number of cells to have approximately 10 million cells in a pellet following collection. The modified nuclear extraction protocol (#40410; Active Motif, Carlsbad, CA, USA) was as follows: The cells were collected by removing the media and washing with 1X ice-cold PBS. This was followed by the addition of 1.5 ml cold PBS and 1 ml trypsin per plate until the cells lifted. The cells were then transferred to a 15 ml centrifuge tube and spun for 5 min at 400 × g at 4°C. The supernatant discarded, and the cells were then rinsed once more with 2 ml ice-cold PBS and spun for 5 min at 400 × g at 4°C and the supernatant was removed. The pellet was resuspended in 1 ml of ice-cold 1X hypotonic buffer, with gentle pipetting up and down and transferring to a chilled 1.5 ml micro-centrifuge tube and incubation on ice for 30 min. Subsequently, 50 µl detergent was added and the mixture was vortexed for 10 sec at the highest setting, and then spun for 2 min at 14,000 × g at 4°C. The supernatant was then transferred (cytoplasmic fraction) into a new chilled micro-centrifuge tube and frozen at -20°C for western blot analysis. The remaining fluid was aspirated until only the pellet remained. The pellet was then rinsed with 1 ml 1X PBS and spun down for 2 min at 14,000 × g at 4°C to aspirate off the supernatant. Nuclear extraction was continued using 50 µl of complete MPER lysis buffer supplemented with protease (#P8340) and phosphatase inhibitors (P0044 and P5726) (both from Sigma-Aldrich) for 30 min on ice. The mixture was then spun for 2 min at 14,000 × g at 4°C, and the supernatant was collected and frozen at -20°C for western blot analysis (nuclear fraction). Protein determination and probing was performed for western blot analysis using the above-mentioned protocol.

A total of 5,000 cells per well (n=12) were counted using a hemocytometer and plated for each of the validated MARCKS mutant lines into black 96-well plates containing 100 µl of DMEM with 10% FBS and 2 µg/ml of the doxycycline (doxycycline medium). The U87 ATP levels were measured using a PerkinElmer ATPlite Luminescence Assay System (PerkinElmer, Waltham, MA, USA) as per the manufacturer’s instructions at 5-7 days after plating. U373 cell viability was determined using same plating conditions (5,000 cells/well 100 µl), however, using a CellTiter Glo (Promega, Madison, WI, USA) kit as per the manufacturer’s protocol (n=4). Luminescence was determined on a BioTek H1 Hybrid Synergy (BioTek, Winooski, VT, USA).

The clonogenic assay was performed as previously described (33). In brief, one-step clonogenic fixation and staining solution were made by combining 750 ml of deionized water with 250 ml of 25% glutaraldehyde (G6257-1L; Sigma-Aldrich) and 5 g of crystal violet (C581-100; Thermo Fisher Scientific) in a 1 liter bottle and mixing at room temperature until the mixture was dissolved. Cells were then doxycycline-induced for 72 h before counting using a hemocytometer and diluting to a defined concentration. Pre-determined cell numbers were plated in 60-mm dishes with a 4 ml total volume and allowed to attach overnight before irradiating in a single fraction at indicated doses for clonogenic assay (colony formation assay does not receive irradiation). Fourteen days after plating, cells were fixed and stained with the clonogenic staining solution for 30 min at room temperature, before gently rinsing plates with cold tap water and drying upside-down overnight. Colonies were counted at ×45 magnification using a dissecting microscope (Stereomaster/Thermo Fisher Scientific, Pittsburgh, PA, USA) and were determined in the presence of >50 cells. The surviving fraction (SF) was calculated by using the following equation: (number of colonies formed/number of cells plated)/(number of colonies from the sham-irradiated group/number of cells plated). Results are plotted in a semi-logarithmic format using GraphPad Prism 7.04 and standard error of the mean (SEM) error bars. Dose enhancement ratio=(dose (Gy) for control (CTL)/dose for ED mutant) at SF=0.2.

In total, 50,000 cells were plated in a 24-well plate containing 12 mm poly-D-Lysine coated round coverslips and 500 µl doxycycline-containing medium. Cells were induced for 72 h before the medium was removed. The cells were then rinsed with 1 ml room temperature PBS and fixed with 500 µl of 4% paraformaldehyde for 12 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 PBS for 20 min and blocked in 5% BSA, 1% goat serum PBS for 40 min at room temperature. Subsequently, 250 µl of 1:250 primary antibody in 0.5% BSA was added per coverslip and incubated overnight at 4°C. Coverslips were rinsed 3 times for 5 min with 500 µl PBS before a 2-h room temperature incubation in the dark with 1:1,000 AlexaFluor 546 anti-rabbit IgG secondary antibody (A11010) and 1X phalloidin-FITC (F432) (both from Invitrogen/Thermo Fisher Scientific) dye in 0.5% BSA PBS. The cells were then rinsed with 500 µl PBS 3 times for 5 min before co-staining with 1:1,000 BlueMask-1 (ChemoMetec, Allerod, Denmark) and 1:250 DAPI (2 µg/ml) at for 30 min at room temperature. Coverslips were rinsed in 500 µl 1X PBS for 5 min before mounting on Xcyto 2-Sample slides (ChemoMetec) with ProLong Glass Antifade mountant with DAPI (Thermo Fisher Scientific) overnight in the dark. Slides were analyzed on the image cytometer Xcyto10 (ChemoMetec) at ×20 magnification with excitation/filter sets AF546 (LED535; 582-636), AF488 (LED488; 513-555), MASK (LED405; 430-475) DAPI (LED405; 573-613) for high-resolution images and the quantification of fluorescent intensities and localization. Similarity scores were calculated using XcytoView (ChemoMetec) and represent the log-transformed Pearson’s correlation coefficients between two channels. Similarity scores between MARCKS and DNA were used to determine MARCKS relative nuclear localization, and similarity scores between MARCKS and phalloidin were used to compare MARCKS and F-actin association.

Cells were adhered to 12 mm poly-D-Lysine-coated round coverslips (REF354086; Corning, Inc., Corning, NY, USA) in 500 µl medium containing doxycycline for 72 h prior to 8 Gy irradiation or 0 Gy (Sham). Cells were fixed at indicated time-points with ice-cold methanol for 12 min at -20°C and blocking with 5% BSA 1% goat serum for 40 min. 1:400 Histone H2AX S139 (9718S; Cell Signaling Technology) primary and 1:1,000 AlexaFluor 488 (ab150077; Abcam) secondary antibodies were used to stain for γH2AX and coverslips were subsequently stained with DAPI and BlueMask-1. Coverslips were mounted slides using with ProLong diamond anti-fade mountant. Cells were imaged on EVOS FL (Thermo Fisher Scientific) microscope at ×20 magnification, with 4 images per time-point collected and were scored by blinded observers. Positive events were defined as ≥10 foci per cell, and the percentage of positive cells per field was graphed using Prism software. The mean nuclear intensity of U373 was acquired using Xcyto10 at a 20X resolution with fluorescent intensities measured using XcytoView. The graph and statistics were generated using GraphPad 7.04 software with error bars in SEM and Log-rank (Mantel-cox) test used to generate the P-values.

The images shown in Figs. 1, S1 and S2 were acquired using a Xcyto10 Image cytometer with a 20X objective lenses on 2 sample slides as follows: Fig. 1 and S1: MARCKS-AF546 (400 msec, LED535; 582-636), phal-loidin-AF488 (400 msec, LED488; 513-555), DAPI (400 msec, LED405; 573-613); Fig. S2: MARCKS-AF546 (800 msec, LED535; 582-636), phalloidin-AF488 (800 msec, LED488; 513-555), DAPI (400 msec, LED405; 573-613). Images were acquired from XcytoView screen captures using linear scale display properties as follows: Figs. 1 and S1: TMARCKS (Min 142, Max 2207), phalloidin (Min 1874, Max 89459); DAPI (Min 1142 Max 16188)]; Fig. S2: TMARCKS (Min 44, Max 5441), phalloidin (Min 868, Max 84947); DAPI (Min 1987 Max 1524)]. The colony formation images shown in Fig. 3C were acquired using a 12 MP camera (Iphone7), and the colony images shown in Fig. 3D were acquired under a dissecting microscope (×45 magnification) using a 12 MP camera (iPhone X). Blots were acquired on an Epson Perfection scanner.

A total of 100,000 cells were plated in 60-mm dishes and induced with doxycycline for 72 h. At 24 h prior to the assay, the medium was exchanged for fresh doxycycline-containing media to remove any floating cells. Cells were irradiated with 16 Gy and collected at the following time-points [immediately post-irradiation (T0), 30 min, 1 h and 4 h] by gently lifting them off the plate into the medium using a rubber policeman. T0 cells were irradiated on ice and scraped immediately following irradiation. The Trevigen Comet assay (Trevigen, Gaithersburg, MD, USA) was used under neutral conditions and manufacturer-provided materials and protocol. Tail moments from 200 cells per spot (3X replicates) were determined using a Zeiss AX10 observer A1 microscope and Comet Assay IV version 4.3 software. The graph was generated using tail moment values in GraphPad 7.04 software.

U87 WT+ cells were cultured to 90% confluence in a 75 cm² flask with standard doxycycline medium for 72 h, prior to trypsin disassociation, rinsing with PBS and flash-freezing in liquid nitrogen. The cells were later lysed in chilled MPER lysis buffer supplemented with protease (#P8340) and phosphatase inhibitors (P0044 and P5726) (both from Sigma-Aldrich) for 30 min on ice. The lysate was centrifuged at 12,000 × g for 10 min at 4°C and protein was quantified by BCA assay. Catch and Release version 2.0 (EMD Millipore, Temecula, CA, USA) was used for immunoprecipitation with the following modifications to the manufacturer’s protocol. 500 µg protein was loaded into a 1.5 ml centrifuge tube, along with a 1:200 dilution of MARCKS antibody (cat. no. 20661-1-AP; Proteintech, Rosemont, IL, USA) or normal rabbit IgG antibody (sc-2027; Santa Cruz Biotechnology). The lysate antibody mixture was rotated at 4°C for 15 min. The lysate antibody mixture was then added to the spin column along with 10 µl affinity ligand and 1X wash buffer for 500 µl total volume. The spin column was rotated overnight at 4°C before proceeding with standard protocol eluting with 70 µl of provided non-denaturing elution buffer. Flow through, washes and elutions were collected for evaluation by western blot analysis before submitting a sample to UAB mass spectrometry core for analysis. The sample was run on 10% Bistris gel and stained using the colloidal blue staining kit (LC60225; Thermo Fisher Scientific) following the manufacturer’s protocol, with fixation for 10 min at room temperature using 50% methanol, 10% acetic acid and staining for 12 h at room temperature. In total, 6 separate fractions were isolated using in-gel digestion with trypsin and analyzed using an nLC LTQ Velos Pro Orbitrap mass spectrometer (Thermo Fisher Scientific) for analysis. Scaffold 4.6.2 was used to compare identified proteins from mass spectrometry experiments and generate Venn diagram. GeneGo 4.9.18 was used to generate network and pathway maps of direct protein interactions from the 108 unique proteins identified in MARCKS immunoprecipitation experiments and not detected in IgG control. Link: https://portal.genego.com/

All animal studies were carried out in accordance with the policies set by the University of Alabama (UAB) Institutional Animal Care and Use Committee (IACUC) and performed according to their guidelines. Moreover, the experimental protocols were registered and approved by the UAB Occupational Health and Safety (Project no. 14-124). Five- to six-week-old female athymic nude mice (Charles River, Hartford, CT, USA) were started on doxycycline chow 1 week prior to an intracranial injection of 500,000 cells per mouse with the aid of UAB’s Brain Tumor Animal Model Core. A total of 40 mice (20 for data shown in Fig. 1A and 20 for data shown in Fig. S3) were used with an average weight of 20-22 g per mouse. All mice were housed under the care and maintenance of UAB’s fully accredited (AAALAC) animal resources program (ARP) with routine monitoring by veterinarians. Mice were housed no more than 6 to a cage and had 24-h access to food and water maintained daily. The animal room was maintained at 21°C and 50% humidity with 12-h light-dark cycles. Intracranial injections were carried out as previously described (36). In brief cells were suspended in a (1:1) mixture of methylcellulose and loaded into a 1 ml Hamilton syringe with a 12-gauge needle. Mice were anesthetized using an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (15 mg/kg), and a midline scalp incision was made and a burr hole was drilled 1 mm posterior to the coronal suture and 2 mm right of the midline. Subsequently, 5 µl of cell mixture was stereotactically delivered to a depth of 2.5 mm into the right caudate-putamen of each mouse. The data shown in Fig. 1A are composed of 4 groups with 5 mice in each (2 with CTL, 2 with WT+) with 1 group of each cell type receiving either 12 Gy (6 by 2 Gy fractions) or sham irradiation (0 Gy). Mice were euthanized at the first appearance of neurological symptoms or at the request of veterinary staff using CO₂ exposure at 20% chamber volume displacement/minute (1.5 l/min in an IACUC approved chamber with a flow meter) for ~5 min followed by secondary cervical dislocation as per the AVMA guidelines. Brains were collected and halved through the injection site for preservation by both formalin and liquid nitrogen.

All statistical analyses were calculated in Prism 8.0 (GraphPad) with P-values <0.05 considered to indicate statistically significant differences. Significance in Fig. 1 was calculated with the Log-rank (Mantel-Cox) test, and in Fig. 2, with the similarity score log-transformed Pearson’s correlation. In Fig. 3, significance (A and B) was determined using one-way ANOVA with Dunnett’s multiple comparison test, or (C) a two tailed t-test. In Fig. 4, significance was determined using two-way ANOVA with Dunnett’s multiple comparison test. All experiments were repeated at least 2 times.

We have previously shown that MARCKS protein expression is inversely associated with GBM proliferation and intracranial xenograft growth rates, with the knockdown of MARCKS in the PTEN-null line, U251, resulting in an enhanced radiation resistance (33). In this study, to establish whether MARCKS overexpression can inhibit GBM growth and enhance radiation sensitivity, we orthotopically implanted the PTEN-null U87 cell line featuring a tetracycline-inducible, V5-tagged MARCKS vector (WT+) (25) or an empty control vector (CTL) into athymic nude mice and assessed the effects on survival. The WT+ mice were found to have a median survival of 31 days without radiotherapy (RT) and a 56-day survival following RT at 12 Gy (25-day enhancement), whereas the CTL mice had a median survival of 22 days without RT and a 42-day median survival with RT (20-day enhancement) (Fig. 1A). MARCKS overexpression increased the survival of the mice compared with the CTL group by 40% (9 days), while the WT+ mice receiving RT had an additional 25% (5 days) increase in survival compared with the CTL mice (Fig. 1A). The successful overexpression of MARCKS in vivo was verified in post-mortem tumors by immunohistochemical staining (Fig. 1B). These data support the hypothesis that the overexpression of MARCKS is capable of suppressing growth and enhancing radiation sensitivity in PTEN-null GBM.

We then investigated the mechanisms through which the phosphorylation of the 4 serine residues present in MARCKS ED affect the ability of MARCKS to suppress GBM growth and radiation resistance by generating additional ED mutants: i) A non-phosphorylatable ED mutant (NP) replaced the serine residues with alanine, to prevent the loss of plasma membrane binding by phosphorylation; ii) a pseudo-phosphorylated ED mutant (PP) substituted the serine residues with aspartic acid, which prevented membrane binding by mimicking negatively charged phosphorylation groups; and iii) a deleted effector domain mutant (ΔED) that lacks an ED (Fig. 2A). To evaluate the cellular localization of the MARCKS mutants, immunofluorescent imaging, and the analysis of the mutants 72 h following doxycycline induction were performed using the image cytometer Xcyto10. An unphosphorylated non-Ca²⁺/CaM bound ED is required for MARCKS membrane binding and F-actin crosslinking (13,37) allowing ΔED to serve as a cytoplasmic control. MARCKS that co-localizes well with F-actin is consistent with an unphosphorylated ED, whereas MARCKS that co-localizes poorly with F-actin may indicate ED phosphorylation or binding to Ca²⁺/CaM (14). Imaging revealed WT+ and NP MARCKS to have substantial co-staining with phalloidin (F-actin stain), while the PP and ΔED MARCKS lacked co-staining with F-actin and appeared predominantly cytoplasmic with perinuclear enrichment. Slight decreases in F-actin intensity were observed in all MARCKS mutants compared with the control (Fig. 2B). Fig. 2C highlights the differences in MARCKS staining between PP and ΔED with minimal F-actin co-staining and prominent perinuclear staining, while NP shows substantial co-staining with F-actin (Fig. 2C). The quantification of MARCKS and F-actin co-staining revealed that both WT+ and NP MARCKS co-stained strongly with F-actin, while the CTL, PP and ΔED lines did not (Fig. 2D). The imaging of uninduced MARCKS U87 mutants can be observed for comparison in Fig. S1. The overexpression of WT+ MARCKS in an additional PTEN-null line (U373) revealed that MARCKS was predominantly membrane-associated and perinuclear with a slight increase in actin co-localization (Fig. S2). These data indicate that the localization of WT+ and NP MARCKS mutants is consistent with an ED that is unphosphorylated and membrane-bound, while the PP mutant mimics the cytoplasmic localization of phosphorylated MARCKS.

To identify differences in GBM growth with MARCKS overexpression and the potential effects of ED phosphorylation, we measured the growth of our MARCKS mutants 7 days following doxycycline induction. Statistically significant (P<0.0001) decreases in growth were observed in the WT+ and NP mutants, and no decrease in growth in PP or ΔED compared to the CTL line (Fig. 3A). The comparison of mutants under PBS and doxycycline conditions is available in Fig. S1 using ATPlite proliferation assay. Colony formation assays revealed NP MARCKS to trend towards (P=0.076) a decrease in colony number compared to CTL, while PP exhibited significant (P=0.001) increases in the number of colonies. WT+ (P=0.61) and ΔED (P=0.85) exhibited no significant differences in colony number (Fig. 3B). Colonies formed by PP were also larger and contained more cells per colony on average compared with CTL and other mutants (Fig. 3C). A magnified view of NP and PP colony differences (solid arrow) can be seen in Fig. 3D. The orthotopic implantation of these ED mutants into mice, however, did not reveal significant differences in survival between the ED mutants, suggesting that MARCKS ED phosphorylation may not fully account for the MARCKS survival benefit (Fig. S3). The growth-suppressive effects of MARCKS overexpression (WT+) were additionally observed in the PTEN-null U373 GBM cell line (P=0.0010) (Fig. 3E), although we lacked NP and PP ED mutants in U373 for additional validation.

Both AKT activation (6) and PKCα protein expression (38) are associated with enhanced cancer growth, proliferation and survival signaling, and the knockdown of MARCKS in GBM has been previously shown to enhance AKT phosphorylation (33) and decrease PKCα levels (32). In this study, we examined the mechanisms through which the overexpression of MARCKS ED mutants affect these features and found that WT+ and NP MARCKS overexpression decreased the activation of AKT (T308 and S473 phosphorylation) by 45 and 32%, respectively compared to the PBS-treated cells, while CTL and PP exhibited negligible suppression. No effects were observed on PKCα expression with the overexpression of our MARCKS mutants (Fig. 3F). Overall, we found that MARCKS overexpression (WT+) suppressed GBM growth and the data suggest that it is the unphosphorylated ED (NP), which suppresses growth and AKT activation, while the phosphorylated ED (PP) does not. Since differences in AKT activation suggest differences in radiation sensitivity (39), we then investigated the effects of MARCKS ED phosphorylation on radiation sensitivity.

Previous experiments in our laboratory have demonstrated that the inhibition of MARCKS ED phosphorylation or the overexpression of NP MARCKS in a lung cancer line sensitized them to radiation (35,40). The GBM data in this study demonstrated that the overexpression of WT+ MARCKS enhanced radiation sensitization in vivo. To determine the mechanisms through which the MARCKS ED phosphorylation state affects radiation sensitivity, we first assessed our mutants using a clonogenic assay. We found NP MARCKS mutants to have the lowest clonogenic survival following escalating doses of radiation, showing radiation sensitization compared with CTL. WT+ exhibited a mild enhancement in radiation sensitivity compared with the control, while PP exhibited slightly decreased sensitivity (dose enhancement ratios at surviving fraction 0.2: CTL =1, WT+ =1.2, N =1.5 and PP =0.87) (Fig. 4A). To investigate potential alterations in DNA repair, we then examined the phosphorylation of histone H2AX at S139 (γH2AX) as a surrogate for DNA damage. At 1 h post-8 Gy single fraction radiotherapy, the WT+ (P=0.0021) and NP (P=0.0111) mutants exhibited prolonged increases in γH2AX levels compared with the control, whereas PP (P=0.0116) exhibited a slight decrease. At 4 h, no statistically significant increases in γH2AX were observed compared with CTL; however, NP did trend towards a significant increase (P=0.2609) (Fig. 4B). Due to the considerable radiation resistance of U87 cells and variations in the cell cycle that alter individual cell radiation sensitivity (41) we used an elevated 16 Gy dose of radiotherapy to directly quantify the formation and resolution of double-strand DNA (dsDNA) breaks using a neutral comet assay (Fig. 4C). NP exhibited the greatest and most significant increases in the tail moment compared to CTL both at 1 h (P<0.0001) and 4 h (P=0.0012) post-irradiation compared with CTL. WT+ had a lower basal amount of DNA damage immediately following 16 Gy (T0) and at 30 min; however at 1 h, WT+ displayed sustained DNA damage (P=0.0067) compared with the control. PP also had a lower induction of double-strand DNA damage immediately following RT and a similar return to baseline as the control (Fig. 4C). The overexpression of WT+ MARCKS in U373 GBM cells similarly revealed increased yH2AX nuclear staining (Fig. S1C) and RT sensitivity measured by clonogenic assay (Fig. 4D), although we lacked ED mutants for additional validation. These data support prior findings that MARCKS is involved in that DNA damage response (33,40) and suggest that an unphosphorylated ED promotes MARCKS radiation sensitization in vitro.

MARCKS is known to be phosphorylated by PKC and ROCK and dephosphorylated by protein phosphatase 2 (PP2A), which alter its ability to bind Ptdlns(4,5)P₂, actin, and Ca²⁺/CaM (10). Recently, MARCKS ED has been shown to function as an NLS allowing it to translocate into the nucleus of GBM and bind nuclear Ptdlns(4,5)P₂ (25). In this study, to identify novel protein-protein interactions of MARCKS in GBM, we immunoprecipitated MARCKS in the WT+ overexpressing U87 cell line and detected protein interactions with high-resolution mass spectrometry. The successful pulldown of MARCKS was verified by western blot analysis before proceeding with in-gel digestion, liquid chromatography and high-resolution mass spectrometry (Fig. 5A). A total of 275 proteins were detected in the two separate MARCKS IP that was not found in the IgG control, 108 of which were identified in both fractions (Fig. 5B). A GeneGo pathway analysis map was constructed from these 108 proteins showing only direct protein interactions (Fig. 5C). A common pathway map was similarly generated in GeneGo to determine the potential signaling interactions of MARCKS (Fig. 5D). The top protein pathway interactions found were involved in cytoskeletal remodeling and the regulation of the actin cytoskeleton and non-homologous end joining (NHEJ) DNA repair pathway. Notable direct protein interactions of interest with MARCKS found using this technique include importin β-2 (transportin-1), a nuclear import chaperone that binds nuclear localization sequences, and Ku70, a protein involved in DNA repair. However, additional validation of these targets at endogenously expressed MARCKS levels is still required.